Erratum: The rationale behind autologous autoimmune hematopoietic stem cell transplant conditioning regimens: Concerns over the use of total body irradiation (Bone Marrow Transplantation (2004) vol. 34 (745-751) 10.1038/sj.bmt.1704671);The rationale behind autologous autoimmune hematopoietic stem cell transplant conditioning regimens: Concerns over the use of total-body irradiation in systemic sclerosis

Bone Marrow Transplantation

Volumn 34, Issue 9, 2004, Pages 745-751

  Burt, R K ^a,h   Kallunian, K ^b   Patel, D ^c   Thomas, J ^d   Yeager, A ^e   Traynor, A ^f   Heipe, F ^g   Arnold, R ^g   Marmont, A ^h   Collier, D ⁱ   Glatstein, E ^j   Snowden, J ^k  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d VANDERBILT UNIVERSITY   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^g HUMBOLDT UNIVERSITY   (Germany)

^h NONE   (United States)

ⁱ UNIVERSITY OF COLORADO   (United States)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

^k UNIVERSITY OF SHEFFIELD   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CAMPTOTHECIN; CARBON MONOXIDE; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DNA; DNA ANTIBODY; DNA TOPOISOMERASE; ETOPOSIDE; FLUDARABINE; GADOLINIUM; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; NONSTEROID ANTIINFLAMMATORY AGENT; RITUXIMAB; THYMOCYTE ANTIBODY; TOPOTECAN; TRANSFORMING GROWTH FACTOR BETA;

ANKYLOSING SPONDYLITIS; AUTOIMMUNE DISEASE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD VESSEL INJURY; BONE MARROW TOXICITY; CLINICAL TRIAL; DATA ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; EDITORIAL; GRAFT REJECTION; HUMAN; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; JUVENILE RHEUMATOID ARTHRITIS; LUNG DIFFUSION CAPACITY; LUNG TOXICITY; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPH NODE IRRADIATION; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DECISION MAKING; MORTALITY; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RADIATION INJURY; RADIOSENSITIVITY; REGISTER; RHEUMATOID ARTHRITIS; SCLERODERMA; SECOND CANCER; SIDE EFFECT; SOLID TUMOR; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TREATMENT INDICATION; TREATMENT PLANNING; VITAL CAPACITY; WHOLE BODY RADIATION;

EID: 7944225009     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704796     Document Type: Erratum

References (69)

1. Tyndall A, Passweg J, Gratwohl A. Haemopoietic stem cell transplantation in the treatment of severe autoimmune diseases. Ann Rheum Dis 2001; 60: 702-707.
2. Binks M, Passweg JR, Furst D et al. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis 2001; 60: 577-584.
3. McSweeney PA, Nash RA, Sullivan KM et al. High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood 2002; 100: 1602-1610.
4. Denton CP, Black CM. Pulmonary hypertension in systemic sclerosis. Rheum Dis Clin N Am 2003; 29: 335-349.
5. Monje ML, Mizumatsu S, Fike JR, Palmer TD. Irradiation induces neural precursor-cell dysfunction. Nat Med 2002; 8: 955-962.
6. Weiner MA, Leventhal B, Brecher ML et al. Randomized study of intensive MOPP-ABVD with or without low-dose total -nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study. J Clin Oncol 1997; 15: 2769-2779.
7. Ferme C, Sebban C, Hennequin C et al. Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin's disease: results of the groupe d'etudes des lymphomes de l'Adulte H89 trial. Blood 2000; 95: 2246-2252.
8. Durelli L, Ferrio MF, Urgesi A et al. Total body irradiation for myasthenia gravis: a long-term follow-up. Neurology 1993; 43: 2215-2221.
9. Smith PG, Doll R. Mortality among patients with ankylosing spondylitis after a single treatment course with x rays. Br Med J Clin Res Ed 1982; 284: 449-460.
10. Calin A, Elswood J. Retrospective analysis of 376 irradiated patients with ankylosing spondylitis and nonirradiated controls. J Rheumatol 1989; 16: 1443-1445.
11. Brown WM, Doll R. Mortality from cancer and other causes after radiotherapy for ankylosing spondylitis. Br Med J 1965; 5474: 1327-1332.
12. Weiss HA, Darby SC, Fearn T, Doll R. Leukemia mortality after X-ray treatment for ankylosing spondylitis. Rad Res 1995; 142 1-11.
13. Weiss HA, Darby SC, Doll R. Cancer mortality following X-ray treatment for ankylosing spondylitis. Int J Cancer 1994; 59: 327-338.
14. Uhrin Z, Wang BW, Matsuda Y et al. Treatment of rheumatoid arthritis with total lymphoid irradiation: long-term survival. Arth Rheum 2001; 44: 1525-1528.
15. Ben-Chetrit E, Gross DJ, Braverman A et al. Total lymphoid irradiation in refractory systemic lupus erythematosus. Ann Int Med 1986; 105: 58-60.
16. Genovese MC, Uhrin Z, Bloch DA et al. Long-term followup of patients treated with total lymphoid irradiation for lupus nephritis. Arth Rheum 2002; 46: 1014-1018.
17. Tanay A, Schiffman G, Strober S. Effect of total lymphoid irradiation on levels of serum autoantibodies in systemic lupus erythematosus and in rheumatoid arthritis. Arth Rheum 1986; 29 26-31.
18. Urowitz MB, Rider WD. Myeloproliferative disorders in patients with rheumatoid arthritis treated with total body irradiation. Am J Med 1985; 78: 60-64.
19. McCurdy D, Tai LQ, Frias S, Wang Z. Delayed repair of DNA damage by ionizing radiation in cells from patients with juvenile systemic lupus erythematosus and rheumatoid arthritis. Rad Res 1997; 147: 48-54.
20. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000; 408: 433-439.
21. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001; 411: 366-374.
22. Ullen H, Bjorkholm E. Localized seleroderma in a woman irradiated at two sites for endometrial and breast carcinoma: a case history and a review of the literature. Int J Gyn Cancer 2003; 13: 77-82.
23. Cooper SG, Denham JW. Progressive systemic sclerosis (diffuse scleroderma) and radiotherapy. Br J Radiol 1990; 63: 804-805.
24. Colver GB, Rodger A, Mortimer PS et al. Post-irradiation morphoea. Br J Dermatol 1989; 120: 831-835.
25. Darras-Joly C, Wechsler B, Bletry O, Piette JC. De novo systemic sclerosis after radiotherapy: a report of 3 cases. J Rheumat 1999; 26: 2265-2267.
26. Davis DA, Cohen PR, McNeese MD, Duvic M. Localized scleroderma in breast cancer patients treated with supervoltage external beam radiation: radiation port scleroderma. J Am Acad Derm 1996; 35: 923-927.
27. Abu-Shakra M, Lee P. Exaggerated fibrosis in patients with systemic sclerosis (scleroderma) following radiation therapy. J Rheumat 1993; 20: 1601-1603.
28. Ransom DT, Cameron FG. Scleroderma - a possible contraindication to lumpectomy and radiotherapy in breast carcinoma. Austral Radiol 1987; 31: 317-318.
29. Trattner A, Figer A, David M et al. Circumscribed scleroderma induced by postlumpectomy radiation therapy. Cancer 1991; 68: 2131-2133.
30. Aref I, Cross P, Nair B. Case report: severe fibrosis in a patient with scleroderma and previous radiotherapy - a case report and literature review. Br J Radiol 1996; 69: 1055-1056.
31. Delanian S, Maulard-Durdux C, Lefaix JL, Housset M. Major interactions between radiation therapy and systemic sclerosis: is there an optimal treatment? Eur J Cancer 1996; 32A: 738-739.
32. Robertson JM, Clarke DH, Pevzner MM, Matter RC. Breast conservation therapy. Severe breast fibrosis after radiation therapy in patients with collagen vascular disease. Cancer 1991; 68: 502-508.
33. Fleck R, McNeese MD, Ellerbroek NA et al. Consequences of breast irradiation in patients with pre-existing collagen vascular diseases. Int J Rad Oncol Biol Phys 1989; 17: 829-833.
34. Varga J, Haustein UF, Creech RH et al. Exaggerated radiation-induced fibrosis in patients with systemic sclerosis. JAMA 1991; 265: 3292-3295.
35. Chen AM, Obedian E, Haffty BG. Breast-conserving therapy in the setting of collagen vascular disease. Cancer J 2001; 7: 480-491.
36. The Steering committee on clinical practice guidelines for the care and treatment of breast cancer. Mastectomy or lumpectomy? The choice of operation for clinical stages I and II breast cancer. Can Med Assoc J 1998; 158 (3 Suppl): S15-S21.
37. O'Dell JR, Steigerwald JC, Kennaugh RC et al. Lack of clinical benefit after treatment of systemic sclerosis with total lymphoid irradiation. J Rheumat 1989; 16: 1050-1054.
38. Law MP. Radiation-induced vascular injury and its relation to late effects in normal tissues. In: Lett J and Adler H (eds). Advances in Radiation Biology, Vol 9. Academic Press: New York, 1981; pp 37-73.
39. Vatistas S, Hornsey S. Radiation-induced protein loss into the gastrointestinal tract. Br J Radiol 1966; 39: 547-550.
40. Bosniak MA, Hardy MA, Quint J, Ghossein NA. Demonstration of the effect of irradiation on canine bowel using in vivo photographic magnification angiography. Radiology 1969; 93: 1361-1368.
41. Keyeux A, Dunjic A, Royer E et al. Late functional and circulatory changes in rats after local irradiation. Int J Rad Biol Rel Stud Phys Chem Med 1971; 20: 7-25.
42. Glatstein E. Alterations in rubidium-86 extraction in normal mouse tissues after irradiation. An estimate of long-term blood flow changes in kidney, lung, liver, skin and muscle. Rad Res 1973; 53: 88-101.
43. Avioli LV, Lazor MZ, Cotlove E et al. Early effects of radiation on renal function in man. Am J Med 1963; 34: 329-337.
44. Tomei F, Papaleo B, Fantini S et al. Vascular effects of occupational exposure to low-dose ionizing radiation. Am J Industr Med 1996; 30: 72-77.
45. Gardiner TA, Amoaku WM, Archer DB. The combined effect of diabetes and ionising radiation on the retinal vasculature of the rat. Curr Eye Res 1993; 12: 1009-1014.
46. Denton CP, Abraham DJ. Transforming growth factor-beta and connective tissue growth factor: key cytokines in scleroderma pathogenesis. Curr Opin Rheumat 2001; 13: 505-511.
47. Pourquier P, Pommier Y. Topoisomerase I-mediated DNA damage. Adv Cancer Res 2001; 80: 189-216.
48. Henry PA, Atamas SP, Yurovsky VV et al. Diversity and plasticity of the anti-DNA topoisomerase I autoantibody response in scleroderma. Arth Rheum 2000; 43: 2733-2742.
49. Seelig HP, Schroter H, Ehrfeld H, Renz M. Autoantibodies against topoisomerase I detected with the natural enzyme and overlapping recombinant peptides. J Immunol Meth 1993; 165: 241-252.
50. D'Arpa P, White-Cooper H, Cleveland DW et al. Use of molecular cloning methods to map the distribution of epitopes on topoisomerase I (Scl-70) recognized by sera of scleroderma patients. Arth Rheum 1990; 33: 1501-1511.
51. Agris PF, Parks R, Bowman L et al. Plant DNA topoisomerase I is recognized and inhibited by human Scl-70 sera autoantibodies. Exp Cell Res 1990; 189: 276-279.
52. Ho KT, Reveille JD. The clinical relevance of autoantibodies in scleroderma. Arth Res Ther 2003; 5: 80-93.
53. Shero JL, Bordwell B, Rothfield NF, Earnshaw WC. High titers of autoantibodies to topoisomerase I (Scl-70) in sera from scleroderma patients. Science 1986; 231: 737-740.
54. Roffler SR, Chan J, Yeh MY. Potentiation of radioimmunotherapy by inhibition of topoisomerase I. Cancer Res 1994; 54: 1276-1285.
55. Chen AY, Choy H, Rothenberg ML. DNA topoisomerase I-targeting drugs as radiation sensitizers. Oncol (Huntington) 1999; 13 (Suppl 5): 39-46.
56. Miyamoto S, Huang TT, Wuerzberger-Davis S et al. Cellular and molecular responses to topoisomerase I poisons. Exploiting synergy for improved radiotherapy. Ann NY Acad Sci 2000; 922: 274-292.
57. Farge D, Marolleau JP, Zohar S et al. Intensification et Autogreffe dans les Maladies Auto Immunes Resistantes (ISAMAIR) Study Group. Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I-II study. Br J Haematol 2002; 119: 726-739.
58. Martini A, Maccario R, Ravelli A et al. Marked and sustained improvement 2 years after autologous stem cell transplantation in a girl with systemic sclerosis. Rheumatism 1999; 38: 773.
59. Rosen O, Thiel A, Massenkeil G et al. Autologous stem cell transplantation in refractory autoimmune diseases after in vivo immunoablation and ex vivo depletion of mononuclear cells. Arth Res 2000; 2: 327-336.
60. Martini A, Maccario R, Ravelli A et al. Marked and sustained improvement two years after autologous stem cell transplantation in a girl with systemic sclerosis. Arth Rheum 1999; 42: 807-811.
61. Tyndall A, Black C, Finke J et al. Treatment of systemic sclerosis with autologous haemopoietic stem cell transplantation. Lancet 1997; 349: 254.
62. Burt RK, Oyama Y, Traynor A et al. Hematopoietic stem cell transplantation for systemic sclerosis with rapid improvement in skin scores: is neoangiogenesis occurring? Bone Marrow Transplant 2003; 32 (Suppl 1): S65-S67.
63. Burt RK, Cohen BA, Russel E et al. Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. Blood 2003; 102: 2373-2378.
64. Inglese M, Mancardi GL, Pagani E et al. Brain tissue loss occurs after suppression of enhancement in patients with multiple sclerosis treated with autologous haemopoietic stem cell transplantation. J Neurol Neurosurg Psychiatry 2004; 75: 643-644.
65. Wulffraat N, van Royen A, Bierings M et al. Autologous haemopoietic stem cell transplantation in four patients with refractory juvenile chronic arthritis. Lancet 1999; 353: 550-553.
66. Burt RK, Cohen B, Stefoski D et al. Non-myeloablative hematopoietic stem cell transplantation for multiple sclerosis. Arch Neurol 2004; In press.
67. Wulffraat NM, Brinkman D, Ferster A et al. Long-term follow-up of autologous stem cell transplantation for refractory juvenile idiopathic arthritis. Bone Marrow Transplant 2003; 32 (Suppl 1): S61-S64.
68. Kashyap A, Passweg J, Tyndall A. Autologous stem cell transplant regimens for the treatment of severe autoimmune diseases. In: Dicke A and Keating A (eds). Autologous Blood and Marrow Transplantation: Proceedings of the Tenth International Symposium. Dallas, TX, Carden Jennings Publishing: Charlottesville, VI, 2001; pp 219-225.
69. White B, Moore WC, Wigley FM et al. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Int Med 2000; 132: 947-954.